This roundtable series assesses the use of antibody-drug conjugates plus chemoimmunotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma setting, as discussed by participants at virtual live events.
Polatuzumab Shows Improved Survival and Complete Responses in R/R DLBCL
July 6th 2022Ian W. Flinn, MD, PhD, discusses the study design and results of the phase 2 trial of the antibody-drug conjugate polatuzumab vedotin-piiq plus bendamustine and rituximab for patients with relapsed/refractory diffuse large B-cell lymphoma.
Real-World Experience With Referral and Access to CAR T-Cell Therapy
December 30th 2022During a Targeted Oncology case-based roundtable event, Christopher R. Flowers, MD, MS, discussed with participants their experiences referring patients for chimeric antigen receptor T-cell therapy and using bridging therapy. This is the first of 2 articles based on this event.
Bridging Options for CAR T-Cell Therapy in R/R DLBCL
January 6th 2023During a Targeted Oncology case-based roundtable event, Christopher R. Flowers, MD, MS, discussed the choice of bridging therapy for a patient with relapsed/refractory diffuse large B-cell lymphoma who may receive CAR (chimeric antigen receptor) T-cell therapy. This is the second of 2 articles based on this event.
Discussing the Investigation of Polatuzumab Combination Therapy in DLBCL
October 24th 2023Elizabeth Lihua Budde, MD, PhD, breaks down the design and baseline characteristics of the phase 3 POLARIX trial that led to the approval of polatuzumab in combination with R-CHP for certain patients with diffuse large B-cell lymphoma.
Immunotherapy in Addition to R-CHOP Improves a SOC in DLBCL
November 15th 2023In the first article of a 2-part series, Herbert A. Eradat, MD, discusses the research down that led to the use of the immunotherapy polatuzumab vedotin in combination with chemotherapy for patients with diffuse large B-cell lymphoma.
Discussing Subgroup Responses to Immunotherapy and R-CHOP in DLBCL
December 6th 2023In the second article of a 2-part series, Herbert A. Eradat, MD, discusses further considerations with adding polatuzumab vedotin in combination chemotherapy in certain subgroups of patients with diffuse large B-cell lymphoma.